A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Inclusion Criteria:
Exclusion criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Canoga Park, California 91304, United States
AAI, C1425BGC, Argentina
CABA, C1280AEB, Argentina
Liège, 4000, Belgium
Ribeirão Preto, 14015 010, Brazil
São José do Rio Preto, 15090 000, Brazil
São Paulo, 05403 900, Brazil
Luoyang, 471003, China
Shanghai, 200023, China
Wenzhou, 325026, China
Praha 1- Mala Strana, 118 33, Czechia
Athens, 12462, Greece
Surat, 395002, India
Negrar-Verona, 37024, Italy
Higashiibaraki-gun, 311-3193, Japan
Kitakyushu, 807-8556, Japan
Nishinomiya Shi, 663 8501, Japan
Shinjuku- Ku, 162-8655, Japan
Shinjuku-ku, 169-0073, Japan
Sunto-gun, 411-8611, Japan
Poznan, 60 354, Poland
Cluj-Napoca, 400061, Romania
Cluj-Napoca, 400394, Romania
Dongdaemun-gu, 02447, South Korea
Allingsas, 441 83, Sweden
Istanbul, 34010, Turkey (Türkiye)
Greater Manchester, BL9 7TD, United Kingdom